<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02963402</url>
  </required_header>
  <id_info>
    <org_study_id>IIBSP-TOC-2016-09</org_study_id>
    <nct_id>NCT02963402</nct_id>
  </id_info>
  <brief_title>Immunoregulatory Mechanisms of Treg Cells Induced by Tocilizumab</brief_title>
  <official_title>Analysis of Immunoregulatory Mechanisms of Treg Cells Induced by Tocilizumab</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      We can speculate that the best responders to tocilizumab should have multiple related
      elements (Treg CD39, adenosine, IL-35) successfully induced and expressed in order to play
      its beneficial role. The study of these elements and its pathways could help identify the
      best responders to tocilizumab treatment.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2016</start_date>
  <primary_completion_date type="Anticipated">March 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Treg phenotype</measure>
    <time_frame>Baseline to 6 months change</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>ATP (adenosine triphosphate)</measure>
    <time_frame>Baseline to 6 months change</time_frame>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Arthritis,Rheumatoid</condition>
  <arm_group>
    <arm_group_label>Tocilizumab treated</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Anti-TNF treated</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tocilizumab</intervention_name>
    <arm_group_label>Tocilizumab treated</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adalimumab</intervention_name>
    <arm_group_label>Anti-TNF treated</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        AR patients treated with tocilizumab in monotherapy or treated with adalimumab as control.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients of all sexes, aged ≥ 18 years.

          -  RA Patients (according to ACR / EULAR criteria 2010) of moderate to severe activity
             (DAS 28&gt; 3.2 or SDAI&gt; 11), and 6 months or more of evolution, starting treatment with
             ACTEMRA (tocilizumab) or with an anti-TNF, according to the product data.

          -  Patients with body weight ≤ 150 kg.

          -  Patients who have received written information about the study and gave their informed
             consent to participate in the study

        Exclusion Criteria:

          -  Patients with a history of autoimmune disease or inflammatory joint disease other than
             RA.

          -  Patients treated with any investigational agent within 4 weeks (or 5 half-lives of
             investigational agent, whichever is greater) before starting treatment with
             tocilizumab
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Silvia Vidal, PhD</last_name>
    <phone>+34935537544</phone>
    <email>svidal@santpau.cat</email>
  </overall_contact>
  <location>
    <facility>
      <name>Insitut de Recerca Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Silvia Vidal, PhD</last_name>
      <phone>+34935537544</phone>
      <email>svidal@santpau.cat</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 10, 2016</study_first_submitted>
  <study_first_submitted_qc>November 10, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 15, 2016</study_first_posted>
  <last_update_submitted>November 10, 2016</last_update_submitted>
  <last_update_submitted_qc>November 10, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 15, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adalimumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

